Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Cartilage Implantation for Focal Chondral Lesions
NCT06897098Phase 1Completed
- Sponsor
- Vanarix
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Implantable Devices, Implantable Hydrogels, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic cartibeads in focal chondral lesion, sponsored by Vanarix. Primary endpoint: Safety at 12 months. Started Jun 2022; status: completed.
02
Drugs
allogeneic cartibeads
03
Conditions
focal chondral lesion
Beyond the preview
Go deeper on NCT06897098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897098.